The aims of the present study were to assess the effect of the oral SIRT1 activator, SRT2104, on measures of arterial compliance in otherwise healthy cigarette smokers and patients with type 2 diabetes. The gene discussed is SIRT1; the disease is type 2 diabetes mellitus.